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Abstract
Background: Vitiligo is a relatively common progressive depigmentary condition that is believed to be
due to the autoimmune-mediated loss of epidermal melanocytes. High frequencies of self-reactive T
lymphocytes directed toward melanocyte differentiation antigens are found in vitiligo patients and might
be directly responsible for the pathogenesis of the disease. An interesting aspect of vitiligo is its relation
to melanoma: cytotoxic T lymphocytes directed to self antigens shared by normal melanocytes and
melanoma cells are found in both conditions, but the resulting immune reactions are completely different.
From this standpoint, the selective destruction of pigment cells that occurs in cases of vitiligo is the
therapeutic goal sought in melanoma research.
Presentation of the hypothesis: Our working hypothesis is that vitiligo patients might represent a
unique source of therapeutic cells to be used in allo-transfer for HLA-matched melanoma patients. The
adoptive transfer of ex-vivo generated autologous tumor-specific T cells is a therapy that has met with only
limited success, essentially because of inability to isolate therapeutically valuable T cells from the majority
of tumor patients. Ideally, model systems where strong and efficient responses against the same (tumor)
antigens are achieved would represent a better source of therapeutic cells. We believe it is possible to
identify one such model in the melanoma-vitiligo dichotomy: T lymphocytes specific for different
melanocyte differentiation antigens are found in vitiligo and represent the effective anti-melanocyte
reactivity that is often ineffective in melanoma.
Testing the hypothesis: Melanocyte-specific T cell clones can be isolated from the peripheral blood of
vitiligo patients and tested for their capacity to efficiently expand in vitro without loosing their cytotoxic
activity and to migrate to the skin. Cytotoxicity against melanoma patients' non-tumor cells can also be
tested. In addition, it would be interesting to attempt an in vivo animal model. If the results obtained from
these validation steps will be satisfactory, it might be possible to plan the clinical grade preparation of
relevant clones for transfer.
Implications of the hypothesis: When translated into a clinical trial, the possibility of in vitro selecting
few effective tumor-specific T cell clones for infusion, inherent with this approach, could enhance the
therapeutic graft-versus-tumor effect while possibly decreasing the risk of graft-versus-host disease.
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Background
Vitiligo is a common skin disease characterized by the
development of white macules and patches associated
with local melanocyte loss [1]. Its etiology is not com-
pletely known, but the observation of circulating
antimelanocytic antibodies and of lymphocytic infiltra-
tions at the margins of lesions in the majority of patients
has lent support to the hypothesis that it is an autoim-
mune disease [2-5].
Many self proteins expressed by melanocytes in the skin of
healthy donors, in non-depigmented skin of vitiligo
patients and in melanoma patients are demonstrably
immunogenic [6-8]. Antigens present in both tumor cells
(melanoma) and their normal cellular counterpart
(melanocytes) are known as melanocyte differentiation
antigens. Among these, Melan-A/MART-1 is a melano-
somal protein whose immunodominant epitope for HLA-
A*0201 was identified by a screening with cytotoxic T
cells [9].
High frequencies of melanocyte-specific CD8+  T lym-
phocytes are found in vitiligo patients. Using HLA/
epitope tetramers, an instrument for measuring the fre-
quency of antigen-specific T cells independently of their
functional state [10], Ogg and co-authors [11] directly
demonstrated for the first time the presence of high fre-
quencies of CD8+ T cells specific for melanocytic antigens
in the peripheral blood of HLA-A*0201+ patients with
autoimmune vitiligo. Following this pioneering study,
other groups [reviewed in [12-14]] contributed, through
the use of tetramers directly ex vivo, without any antigen-
specific stimulation, to the demonstration that melano-
cyte-specific CD8+ cells are present in the peripheral blood
of both melanoma and vitiligo patients. In particular,
high numbers of Melan-A/MART1-specific cells were
detected in the majority of patients. Besides circulating
cells, melanocyte-specific CD8+ T lymphocytes were also
observed in situ in both depigmenting lesions of patients
with vitiligo [15,16].
These melanocyte-specific CD8+ T Lymphocytes might be
relevant for the pathogenesis of vitiligo. The first sugges-
tions came from rare case reports on inflammatory vitiligo
[17,18] and immunohistochemical studies later on con-
firmed the presence of infiltrating T cells in apposition to
perilesional melanocytes [19]. Importantly, similar in situ
T cell infiltrates were also detected in the more common
form of the disease, generalized vitiligo [20-22]. Further
indications favoring a pathogenetic role for melanocyte-
specific, CD8+ T cells in vitiligo came from the direct cor-
relation between their frequency within the total T cell
pool and disease activity [11,23], as well as from their
capacity to kill HLA-matched tumor cells [11,24,25] and,
most notably, normal matched melanocytes [16,26].
Melanoma is an aggressive form of tumor whose inci-
dence increases by 5% per year. Although the presence of
melanoma-specific CTLs in cancer patients demonstrate
that tumor cells may not completely evade immune recog-
nition, the patient's immune system can only rarely coun-
teract tumor growth [27-29]. An unusual facet of vitiligo
is its relation to melanoma: cytotoxic T lymphocytes
directed at self antigens shared by normal melanocytes
and melanoma cells are found in both conditions and
suggest a breakdown of tolerance [11,30-34], yet the
resulting immune reaction is the opposite [35-37]. In
vitiligo, natural immune tolerance is over-ridden such
that the host immune system can orchestrate melanocyte
destruction, whereas in melanoma, an immune effector
function of potential benefit to the host, i.e., efficient
destruction of transformed melanocytes, does occur very
rarely. In this respect, it would seem that reactivity to vitil-
igo melanocytes may be the effective variant of an
immune response often ineffective in melanoma. The
mechanisms causing these opposite effects are not known
but these data, together with the resistance of melanoma
to conventional chemotherapeutic and radiotherapeutic
approaches, have made the melanoma/vitiligo dichotomy
an important model for immunologic investigation.
Avidity of antigen recognition is an important feature of
tumor-specific T lymphocytes, determining their capabil-
ity to kill tumor cells. Notably, a few recent studies indi-
cated that Melan-A/MART1-specific CD8+ T cells isolated
from vitiligo patients possess an increased avidity and
exert a superior anti-tumor activity than those from
melanoma [24,25]. Further indications come from ani-
mal models. In one recent study [38] MT-ret transgenic
mice, a model for human cutaneous melanoma, were
used to investigate the natural anti-tumor T cell response.
A large proportion of these animals developed
melanoma-associated vitiligo and a good correlation was
found between vitiligo development and melanoma con-
trol. Interestingly, T cells that secreted IFN-γ in response to
melanoma cells were statistically more frequent in
melanoma mice that developed vitiligo than in mice that
did not, suggesting that vitiligo-associated T cells pos-
sessed an increased functional avidity. These data suggest
that a qualitative difference exists between the anti-
melanocyte cytotoxic T cell responses found in vitiligo
versus melanoma that might explain the opposite immu-
nologic outcomes.
Presentation of the Hypothesis
Autoimmune conditions stem from a break of tolerance
to defined autoantigens and this allows for the produc-
tion of high avidity antigen-specific responses. If these
antigens are also relevant to tumor immunity, autoim-
mune cells can be exploited for tumor intervention. Our
working hypothesis is that vitiligo patients might repre-Journal of Autoimmune Diseases 2005, 2:7 http://www.jautoimdis.com/content/2/1/7
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sent a unique source of therapeutic cells for HLA-matched
melanoma patients, essentially due to their superior TCR
affinity and increased tumoricidal potential.
The adoptive transfer of ex-vivo  generated autologous
tumor-specific T cells is a potentially potent therapy that
has met with only limited success. An important limita-
tion to such treatment is inability to isolate and generate
therapeutically valuable T cells from the majority of
tumor patients. The causes of these limitations are not
well known, but might include the inability of the tumor
cells to trigger a T-cell response (ignorance) or their ability
to actively suppress or delete T cells of the highest avidity
(tolerance). In addition, T cells derived from melanoma
patients may often display functional impairments as a
consequence of the tumor environment, which inhibits
their acquisition of final effector functions [32]. Indeed, in
vitro culture of these tumor-sensitized T cells with appro-
priate activation stimuli has been shown to partially
restore normal functional properties [39] and to confer
effector activity that could potentially sustain tumor rejec-
tion upon re-infusion [40]. However, in the majority of
cases, autologous T cells are found to exert only poor cyto-
toxic activity toward HLA matched melanoma cells. On
the other hand, CTLs against different melanoma associ-
ated antigen are found in vitiligo and mediate autologous
melanocyte destruction [24-26,30,31]. Notably, the
Melan-A/MART1-specific CD8+ T cells isolated from vitil-
igo patients appear to possess an increased avidity and to
exert a superior anti-tumor activity than those from
melanoma [24-26].
How can this knowledge be applied to the definition of
new immunotherapeutic strategies for melanoma
patients? A first possibility is an allo-transfer approach,
where very efficient anti-tumor CD8+ T lymphocytes from
vitiligo donors can be transferred into HLA-matched
melanoma patients. High-avidity and tumor-specific T
cell clones can be isolated from the peripheral blood of
HLA-A2 vitiligo patients; if these could be proven to effi-
ciently expand in vitro without loosing their cytotoxic
activity and to maintain their skin-homing capability,
they might represent a valuable source of therapeutic cells.
Testing the Hypothesis
In order to test the hypothesis, melanocyte-specific T cell
clones could be tetramer-sorted from the peripheral blood
of vitiligo patients and tested for their capacity to effi-
ciently expand in vitro without loosing their cytotoxic
activity. They will also be tested for their skin-homing
activity by FACS-evaluating surface expression of the cuta-
neous lymphocyte antigen, CLA. As a first effort in deter-
mining the effects of host cellular environment on allo-
transfer, these cells can be mixed with PBMC from HLA-
matched melanoma patients and the anti-tumor potential
of the vitiligo/melanoma pools assayed. Possible immu-
nosuppressor effects exerted by either the melanoma
patients' sera [41] or the tumor itself might be addressed
through co-cultures. Cytotoxicity against melanoma
patients' non-tumor cells (peripheral blood, skin biop-
sies) can also be tested. In addition, it would be interest-
ing to attempt an in vivo animal model using
immunodeficient SCID or RAG knockout mice, rendered
transgenic for human HLA and transplanted with
melanoma. These mice might be treated with the clone
from a vitiligo patient, with or without melanoma
patient's lymphocytes. If the results obtained from both
the in vitro validation step and the in vivo animal model
will be satisfactory, it will be possible to plan the clinical
grade preparation of relevant clones for transfer. A major
drawback of this approach remains achievement of HLA
match between a T cell donor and a melanoma patient.
Only weak associations between vitiligo and several HLA-
class I and -class II alleles have been reported to date, and
essentially no significant association exists with
melanoma. So, as patients with vitiligo represent about
1% of the general population, the probability to find a
perfect match can be estimated to be a hundred-time
lower than the one theoretically achieved for allogeneic
transplantation involving the entire population as poten-
tial donors.
Implications of the Hypothesis
If this hypothesis were true, at least some autoimmune
diseases might be seen as novel sources of therapeutic
cells for tumor patients. When translated into a clinical
trial, the possibility of in vitro selecting few tumor-specific
T cell clones for infusion, inherent with this approach,
could enhance the therapeutic graft-versus-tumor effect
while possibly decreasing the risk of graft-versus-host dis-
ease.
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